TY - JOUR
T1 - Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension
T2 - A Consensus Document From the Hypertension Academic Research Consortium
AU - Kandzari, David E.
AU - Mahfoud, Felix
AU - Weber, Michael A.
AU - Townsend, Raymond
AU - Parati, Gianfranco
AU - Fisher, Naomi D.L.
AU - Lobo, Melvin D.
AU - Bloch, Michael
AU - Böhm, Michael
AU - Sharp, Andrew S.P.
AU - Schmieder, Roland E.
AU - Azizi, Michel
AU - Schlaich, Markus P.
AU - Papademetriou, Vasilios
AU - Kirtane, Ajay J.
AU - Daemen, Joost
AU - Pathak, Atul
AU - Ukena, Christian
AU - Lurz, Philipp
AU - Grassi, Guido
AU - Myers, Martin
AU - Finn, Aloke V.
AU - Morice, Marie Claude
AU - Mehran, Roxana
AU - Jüni, Peter
AU - Stone, Gregg W.
AU - Krucoff, Mitchell W.
AU - Whelton, Paul K.
AU - Tsioufis, Konstantinos
AU - Cutlip, Donald E.
AU - Spitzer, Ernest
N1 - Publisher Copyright:
© 2022 Lippincott Williams and Wilkins. All rights reserved.
PY - 2022/3/15
Y1 - 2022/3/15
N2 - The clinical implications of hypertension in addition to a high prevalence of both uncontrolled blood pressure and medication nonadherence promote interest in developing device-based approaches to hypertension treatment. The expansion of device-based therapies and ongoing clinical trials underscores the need for consistency in trial design, conduct, and definitions of clinical study elements to permit trial comparability and data poolability. Standardizing methods of blood pressure assessment, effectiveness measures beyond blood pressure alone, and safety outcomes are paramount. The Hypertension Academic Research Consortium (HARC) document represents an integration of evolving evidence and consensus opinion among leading experts in cardiovascular medicine and hypertension research with regulatory perspectives on clinical trial design and methodology. The HARC document integrates the collective information among device-based therapies for hypertension to better address existing challenges and identify unmet needs for technologies proposed to treat the world's leading cause of death and disability. Consistent with the Academic Research Consortium charter, this document proposes pragmatic consensus clinical design principles and outcomes definitions for studies aimed at evaluating device-based hypertension therapies.
AB - The clinical implications of hypertension in addition to a high prevalence of both uncontrolled blood pressure and medication nonadherence promote interest in developing device-based approaches to hypertension treatment. The expansion of device-based therapies and ongoing clinical trials underscores the need for consistency in trial design, conduct, and definitions of clinical study elements to permit trial comparability and data poolability. Standardizing methods of blood pressure assessment, effectiveness measures beyond blood pressure alone, and safety outcomes are paramount. The Hypertension Academic Research Consortium (HARC) document represents an integration of evolving evidence and consensus opinion among leading experts in cardiovascular medicine and hypertension research with regulatory perspectives on clinical trial design and methodology. The HARC document integrates the collective information among device-based therapies for hypertension to better address existing challenges and identify unmet needs for technologies proposed to treat the world's leading cause of death and disability. Consistent with the Academic Research Consortium charter, this document proposes pragmatic consensus clinical design principles and outcomes definitions for studies aimed at evaluating device-based hypertension therapies.
UR - http://www.scopus.com/inward/record.url?scp=85126725195&partnerID=8YFLogxK
U2 - 10.1161/CIRCULATIONAHA.121.057687
DO - 10.1161/CIRCULATIONAHA.121.057687
M3 - Review article
C2 - 35286164
AN - SCOPUS:85126725195
SN - 0009-7322
VL - 145
SP - 847
EP - 863
JO - Circulation
JF - Circulation
IS - 11
ER -